June 2, 2017
ICER’s report on opioid ADFs lays out several important facts. First, pain is a significant medical problem with potentially devastating…
April 24, 2017
The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients’ access to the treatments will be.
February 24, 2017
The Institute for Clinical and Economic Review has issued a draft report concluding that targeted immune modulators, such as biologic treatments, for rheumatoid arthritis are too expensive. The conclusion could embolden health plans to limit patient access.
But does ICER’s model accurately reflect the experiences of the 1.5 million Americans with rheumatoid arthritis?
October 23, 2016
What happens when patients’ medications are switched for financial reasons instead of medical reasons? Does it affect their health? Their…
October 20, 2016
As ICER’s draft report acknowledges, plaque psoriasis is a common disease that can impact patients’ quality of life and daily…
September 23, 2016
Under prevailing benefit designs in both public and private health insurance systems, patients may find that pivotal decisions about their…
September 12, 2016
In light of the ICER value framework’s impact on health care, patients and physicians across the United States, we offer the following 12 suggestions for the updated framework to be implemented in 2017. These suggestions focus primarily on two areas for which ICER requested feedback: 1) Integration of patient and clinician perspectives on the value of interventions, and 2) Incremental cost-effectiveness ratios and thresholds.
